Brief: Abpro Finalizes Strategic Partnership With Celltrion For Worldwide Development And Commercialization Of Cancer Treatment Bispecific Antibody
21/09/2022 14:34
Sept 21 (Reuters) - Celltrion Inc 068270.KS :
* ABPRO FINALIZES STRATEGIC PARTNERSHIP WITH CELLTRION FOR
WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION OF A CANCER
TREATMENT BISPECIFIC ANTIBODY
Source text for Eikon: ID:nBw8C4GFRa
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won